From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Our industry-leading GTN suite and consulting services improve your pharmaceutical forecast accuracy, modeling, and financial close efficiency, enabling greater visibility, control, and optimization of net revenue.
With ICyte, pharmaceutical finance and market access teams can build, maintain, and support financial models that can accurately forecast net revenue by payer and channeland effectively avoid the most common challenges:
Our industry-leading GTN forecasting software enables manufacturers to better estimate the actual revenue, better manage inventory levels and avoid overstocking or understocking products, negotiate with payers more effectively and avoid overcommitting to discounts, and make faster and more data-driven pricing decisions. Offered as Software-as-a-Service (SaaS), Business Process-as-a-Service (BPaaS), and hybrid operating models, our solutions enable you to achieve full visibility and traceability to historical inputs, forecasts, modeling scenarios, underlying assumptions, and transactions.
Our industry-standard forecasting methodologies in pharmaceutical manufacturing are configured for each liability line item with the ability to execute multiple scenario analyses for forecasts along with functionality to compare scenarios, including:
IntegriChain’s GTN Forecasting is part of our broader GTN solution that delivers on four distinct types of capabilities:
Excel in Pharmaceutical Software
Whether manufacturers are entering new therapeutic categories, exploring new indications for a current product, or looking to acquire a new product through acquisition, portfolio growth presents both opportunities and challenges.
Read the Blog
In the current pharmaceutical landscape, more than 80% of manufacturers still rely on manual processes to accrue, forecast, and report their gross-to-net (GTN) deductions. However, in the era of big data and technological enhancements, manual processes cannot be relied on forever.
